MedTrace Logo

ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial

NCT02348905 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2015-01-28

No results posted yet for this study

Summary

ACTHAR gel has efficacy in the treatment of cutaneous sarcoidosis

Conditions

  • Sarcoidosis
  • Cutaneous Sarcoidosis

Interventions

DRUG

ACTHAR Gel 40 units twice weekly

ACTHAR Gel (adrenocorticotropic hormone) 40 units twice weekly between Baseline and week 12.

DRUG

ACTHAR Gel 80 units twice weekly.

ACTHAR Gel (adrenocorticotropic hormone) 80 units twice weekly between Baseline and week 12.

Sponsors & Collaborators

  • Albany Medical College

    lead OTHER

Principal Investigators

  • Marc A Judson, MD · Albany Medical College

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2015-07-31
Completion
2016-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02348905 on ClinicalTrials.gov